PEGPH20 Shows Doubling of PFS in Pancreatic Cancer Patients with High Levels of Hyaluronan in Phase II Trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Interim findings from an ongoing phase II clinical study of PEGPH20 showed a doubling of progression-free survival and an improvement trend in overall survival in metastatic pancreatic cancer patients with high levels of hyaluronan.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Health and Human Services Secretary Robert F. Kennedy Jr. is moving to overhaul the U.S. Preventive Services Task Force, a highly influential panel that determines which preventive services insurers must cover and guides routine medical care for millions of Americans. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login